Cite
HARVARD Citation
Jiang, Z. et al. (n.d.). 283O_PRPhase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer. Annals of oncology. p. . [Online].